Premium
Identification of proteins secreted by head and neck cancer cell lines using LC‐MS/MS: Strategy for discovery of candidate serological biomarkers
Author(s) -
Ralhan Ranju,
Masui Olena,
DeSouza Leroi V.,
Matta Ajay,
Macha Muzafar,
Siu K. W. Michael
Publication year - 2011
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201000186
Subject(s) - serology , biomarker discovery , proteomics , identification (biology) , computational biology , biology , antibody , biochemistry , immunology , gene , botany
In search of blood‐based biomarkers that would enhance the ability to diagnose head and neck/oral squamous cell carcinoma (HNOSCC) in early stages or predict its prognosis, we analyzed the HNOSCC secretome (ensemble of proteins secreted and/or shed from the tumor cells) for potential biomarkers using proteomic technologies. LC‐MS/MS was used to identify proteins in the conditioned media of four HNOSCC cell lines (SCC4, HSC2, SCC38, and AMOSIII); 140 unique proteins were identified on the basis of 5% global false discovery rate, 122 of which were secretory proteins, with 29 being previously reported to be overexpressed in HNOSCC in comparison to normal head and neck tissues. Of these, five proteins including α‐enolase, peptidyl prolyl isomerase A/cyclophilin A, 14‐3‐3 ζ, heterogeneous ribonucleoprotein K, and 14‐3‐3 σ were detected in the sera of HNOSCC patients by Western blot analysis. Our study provides the evidence that analysis of head and neck cancer cells' secretome is a viable strategy for identifying candidate serological biomarkers for HNOSCC. In future, these biomarkers may be useful in predicting the likelihood of transformation of oral pre‐malignant lesions, prognosis of HNOSCC patients and evaluate response to therapy using minimally invasive tests.